Walvax Biotechnology

company

About

Walvax Biotechnology Co., Ltd., a biological pharmaceutical company

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$72.80M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2001
Number Of Employee
11 - 50
Operating Status
Active
Stock Symbol
szse:300142

Walvax Biotechnology Co., Ltd., a biological pharmaceutical company, is engaged in the research and development, production, and sale of bio-medicine products in the People’s Republic of China. It provides bio-medicines, such as vaccines, blood products, and others. The company offers Group A and C meningococcal polysaccharide vaccine for children and adults over the age of 2 years to prevent disease caused by the bacteria named neisseria meningitidis groups A and group C; and haemophilus influenzae type b conjugate vaccine for infants from the age of 2 months to 5 years to induce immunization against infectious diseases, such as meningitis, pneumonia, septicemia, cellulitis, arthritis, and epiglottitis, etc. It also provides prefilled syringe dosage form of haemophilus influenzae type b conjugate vaccine; Group A, C meningococcal polysaccharide conjugate vaccine for infants from the age of 3 months to 5 years preventing diseases, such as cerebrospinal meningitis and septicemia; and Group ACYW135 meningococcal polysaccharide vaccine for children above 2 years old to prevent meningococcal disease caused by epidemic Neisseria meningitidis serogroups A, C, Y, and W-135. The company was founded in 2001 and is headquartered in Kunming, the People’s Republic of China.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$72.80M
Walvax Biotechnology has raised a total of $72.80M in funding over 2 rounds. Their latest funding was raised on Aug 8, 2014 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 8, 2014 Post-IPO Equity $72.80M Detail
Nov 12, 2010 IPO Detail

Investments

Number of Investments
Number of Lead Investments
1
1
Walvax Biotechnology has made 1 investments. Their most recent investment was on Oct 23, 2020, when Sirnaomics raised $105M.
Date Company Name
Round Money Raised Industry Lead Investor
Oct 23, 2020 Sirnaomics
Series D $105M Biopharma Yes

Employee Profiles

Number of Employee Profiles
3
Walvax Biotechnology has 3 current employee profiles, including Board member Yunchun Li
Board member
Executive
Executive

Acquisition

Walvax Biotechnology has acquired 1 organizations. Their most recent acquisition was Hebei Daan Pharmaceutical Co., Ltd on Oct 26, 2012. They acquired Hebei Daan Pharmaceutical Co., Ltd for ¥529M.

Date Company Name
Industry Acquisition Type Price
Health Care ¥ 529M Detail